MenQuadfi
meningococcal group A, C, W-135 and Y conjugate vaccine
Table of contents
Overview
MenQuadfi is a vaccine used to protect adults and children from the age of 12 months against invasive meningococcal disease caused by four groups of the Neisseria meningitidis bacteria (group A, C, W, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).
The vaccine contains substances from the outer coat of N. meningitidis bacteria.
-
List item
MenQuadfi : EPAR - Medicine overview (PDF/123.1 KB)
First published: 27/11/2020
EMA/537720/2020 -
-
List item
MenQuadfi : EPAR - Risk-management-plan summary (PDF/474.14 KB)
First published: 27/11/2020
Last updated: 17/01/2023
Authorisation details
Product details | |
---|---|
Name |
MenQuadfi
|
Agency product number |
EMEA/H/C/005084
|
Active substance |
|
International non-proprietary name (INN) or common name |
meningococcal group A, C, W-135 and Y conjugate vaccine
|
Therapeutic area (MeSH) |
Meningitis, Meningococcal
|
Anatomical therapeutic chemical (ATC) code |
J07AH08
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Sanofi Pasteur
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
18/11/2020
|
Contact address |
14 Espace Henry Vallée |
Product information
27/02/2023 MenQuadfi - EMEA/H/C/005084 - N/0021
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
The use of this vaccine should be in accordance with available official recommendations.